Pacific Biosciences Of California | PACB - Cash And Equivalent


Pacific Biosciences Of California reported $279.51M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Agilent USD 1.76B 31M Dec/2025
Bruker USD 293.1M 201.1M Sep/2025
Danaher USD 4.62B 3.09B Dec/2025
General Electric Aerospace USD 12.39B 109M Dec/2025
Illumina USD 1.42B 368M Dec/2025
Myriad Genetics USD 149.6M 4.2M Dec/2025
Pacific Biosciences Of California USD 279.51M 223.04M Dec/2025
Quidel USD 169.8M 71.7M Dec/2025
Revvity USD 919.86M 11.53M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Standard Biotools USD 118.21M 11.2M Dec/2025
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025
Waters USD 587.83M 128.71M Dec/2025